BLLN (BillionToOne) ROCE %: 12.06% (As of Mar. 2026)


BLLN BillionToOne Inc BLLN
13 GF Score
Price $122.33
! 5 Warning Signs
View Full Analysis

What is BillionToOne ROCE %?

BillionToOne BLLN +2.04% 13 ROCE % is 12.06% as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BillionToOne's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.06%.

BillionToOne  (NAS:BLLN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BillionToOne ROCE % Related Terms

BillionToOne ROCE % Historical Data

* Premium members only.

The historical data trend for BillionToOne's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne ROCE % Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
-63.59 -19.65 1.83

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial -5.62 -0.29 8.01 5.78 12.06
BLLN
13GF Score
BillionToOne Inc BLLN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne ROCE % Calculation

BillionToOne's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=7.854/( ( (302.059 - 28.386) + (632.654 - 47.962) )/ 2 )
=7.854/( (273.673+584.692)/ 2 )
=7.854/429.1825
=1.83 %

BillionToOne's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=74.076/( ( (632.654 - 47.962) + (700.727 - 57.162) )/ 2 )
=74.076/( ( 584.692 + 643.565 )/ 2 )
=74.076/614.1285
=12.06 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.06% mean?
BillionToOne (BLLN) has a ROCE % of 12.06% as of Mar. 2026.
Is BillionToOne's ROCE % too high?
BillionToOne's current ROCE % is 12.06%. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's ROCE % compare to SHC and VCYT?
BillionToOne's ROCE % of 12.06% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. BillionToOne's current ROCE % is 12.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current ROCE % of 12.06%. The current ROCE % is 12.06%. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For BillionToOne (BLLN), the current ROCE % is 12.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score

Get the complete analysis for BLLN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.33
Price